Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Suppression of EZH2 accelerates MYC-driven lymphomagenesis by inhibition of apoptosis
    Meeting Abstract

    Appelmann, I.; Scuoppo, C.; Thapar, V.; Ledezma, D.; Lujambio, A.; Lowe, S. W.; Chicas, A.
    Blood (2014)

    Fulltext@MSK | Save
  • Autologous hematopoietic stem cell transplantation (AHCT) in patients with chemotherapy-sensitive, relapsed/refractory (CSRR) human immunodeficiency virus (HIV)-associated lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) trial
    Meeting Abstract

    Alvarnas, J.; Le-Rademacher, J.; Wang, Y.; Little, R. F.; Akpek, G.; Ayala, E.; Devine, S.; Kaplan, L.; Noy, A.; Popat, U.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Femoral bone marrow aspiration in live mice
    Journal Article

    Chung, Y. R.; Kim, E.; Abdel-Wahab, O.
    Journal of Visualized Experiments (2014)

    Fulltext@MSK | Save
  • Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Meeting Abstract

    Sharman, J.; Coutre, S.; Furman, R.; Cheson, B.; Pagel, J.; Hillmen, P.; Barrientos, J.; Zelenetz, A.; Kipps, T.; Flinn, I.; more...
    Leukemia Research (2014)

    Fulltext@MSK | Save
  • Targeting the cell cycle regulated CDC7 kinase pathway as a novel therapeutic approach for hematologic malignancies
    Meeting Abstract

    Santos, R.; Shum, D.; Churchill, M.; Mukherjee, S.; Brentjens, R. J.; Jurcic, J. G.; Kelly, T.; Djaballah, H.; Frattini, M. G.
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save
  • Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumors
    Meeting Abstract

    Santos, R.; Shum, D.; Carrillo, D.; Zhang, R.; Churchill, M.; Mukherjee, S.; Brentjens, R.; Radu, C.; Kelly, T. J.; Djaballah, H.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeutics
    Meeting Abstract

    Reimer, J.; Kovulchuk, A.; Ruan, Y.; Shah, R.; Jayanthan, A.; Perinpanayagam, M.; Truong, T.; Auer-Grzesiak, I.; Luider, J.; Kovulchuk, O.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
    Meeting Abstract

    Pollyea, D. A.; de Botton, S.; Fathi, A. T.; Stein, E. M.; Tallman, M. S.; Agresta, S.; Bowden, C.; Fan, B.; Prah, M.; Yang, H.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase 1 study
    Meeting Abstract

    Mauro, M. J.; Cortes, J. E.; Kantarjian, H. M.; Shah, N. P.; Bixby, D.; Flinn, I. W.; O'Hare, T.; Hu, S. M.; Rivera, V. M.; Clackson, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save